JPRN-jRCT2031200270进行中（未招募）1 期
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 erbumine as a Single Agent and in Combination in Patients with Relapsed/Refractory Neuroblastoma - J1O-MC-JZHD
Masaki Takeshi0 个研究点目标入组 5 人开始时间: 2020年12月24日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 2age old 至 <= 21age old（—）
- 性别
- All
入选标准
- •Participants must have relapsed/refractory neuroblastoma and have active disease in at least one site: bone, bone marrow or soft tissue. Participants must be able to submit an archival sample of tissue.
- •- Participants must be able to swallow capsules.
排除标准
- •- Participants must not have had an allogeneic hematopoietic stem cell, bone marrow, or solid organ transplant.
- •- Participants must not have untreated tumor that has spread to the brain or spinal cord.
- •- Participant s must not have a serious active disease other than neuroblastoma.
- •- Participants must not have a condition affecting absorption.
- •- Participants must not have had prior aurora kinase inhibitor exposure.
- •- Participants must not have a known allergy to the study treatment.
- •- Participants must not have symptomatic human immunodeficiency virus (HIV) infection or symptomatic activated/reactivated hepatitis A, B, or C.
研究者
相似试验
进行中（未招募）
1 期
A Phase 1 Study of LY3295668 Erbumine Monotherapy and in Combination in Patients with Relapsed/Refractory NeuroblastomaRelapsed/Refractory NeuroblastomaMedDRA version: 20.0Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-001042-18-BEEli Lilly and Company71
进行中（未招募）
1 期
A Phase 1 Study of LY3295668 Erbumine Monotherapy and in Combination in Patients with Relapsed/Refractory NeuroblastomaRelapsed/Refractory NeuroblastomaMedDRA version: 20.0Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-001042-18-ESilly SA71
进行中（未招募）
1 期
A Phase 1 Study of LY3295668 Erbumine Monotherapy and in Combination in Patients with Relapsed/Refractory NeuroblastomaEUCTR2019-001042-18-FREli Lilly and Company71
进行中（未招募）
1 期
A Phase 1 Study of LY3295668 Erbumine Monotherapy and in Combination in Patients with Relapsed/Refractory NeuroblastomaRelapsed/Refractory NeuroblastomaMedDRA version: 20.0Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-001042-18-DEEli Lilly and Company71
进行中（未招募）
1 期
A Phase 1 Study of LY3295668 Erbumine Monotherapy and in Combination in Patients with Relapsed/Refractory NeuroblastomaRelapsed/Refractory NeuroblastomaMedDRA version: 20.0Level: PTClassification code 10029260Term: NeuroblastomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-001042-18-GBEli Lilly and Company71